The eagerly awaited results of the BrighTNess study confirm the benefit of adding carboplatin to standard chemotherapy in triple negative breast cancer (TNBC), but show no additional benefit with the PARP inhibitor velirapib. In a phase 3 randomised controlled trial involving 634 women with TNBC, the proportion who achieved a pathological complete response was 58% ...
Carboplatin the new standard of care in triple negative breast cancer: BRIGHTNESS
By Michael Woodhead
6 Mar 2018